In addition, some preclinical studies have demonstrated that inhibition of HMGB1 release by EP significantly increased the tumor cell sensitivity to other anticancer agents [17], and also protected against chemotherapy-induced cytotoxicity [45]. Here, HMGB1 is linked to neoplasm.